All patients
Age < 65y (younger) Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L1 - all population, Immune checkpoint association vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 9LA, 2021 0.69 [0.55; 0.87]
MYSTIC (DT ; all population), 2020 0.94 [0.80; 1.11]
0.81 [0.60 ; 1.10 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 78% 1,463 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 9LA, 2021 0.66 [0.55; 0.80]
0.66 [0.55 ; 0.80 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable PFS (extension)detailed results CheckMate 9LA, 2021 0.68 [0.57; 0.82]
0.68 [0.57 ; 0.82 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable progression or deaths (PFS)detailed results CheckMate 9LA, 2021 0.70 [0.57; 0.86]
0.70 [0.57 ; 0.86 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable objective responses (ORR)detailed results CheckMate 9LA, 2021 1.80 [1.31; 2.48]
1.80 [1.31 ; 2.48 ] CheckMate 9LA, 2021 1 0% 719 NA not evaluable AE (any grade)detailed results MYSTIC (DT ; all population), 2020 0.51 [0.27; 0.96]
0.51 [0.27 ; 0.96 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.02 [0.76; 1.37]
1.02 [0.76 ; 1.37 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable AE leading to death (grade 5)detailed results MYSTIC (DT ; all population), 2020 2.19 [1.17; 4.11]
2.19 [1.17 ; 4.11 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results MYSTIC (DT ; all population), 2020 1.43 [0.97; 2.10]
1.43 [0.97 ; 2.10 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.14 [1.32; 3.47]
2.14 [1.32 ; 3.47 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable STRAE (any grade)detailed results CheckMate 9LA, 2021 1.94 [1.36; 2.76]
MYSTIC (DT ; all population), 2020 1.52 [1.03; 2.24]
1.73 [1.33 ; 2.25 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.95 [1.33; 2.84]
MYSTIC (DT ; all population), 2020 1.43 [0.92; 2.21]
1.70 [1.26 ; 2.30 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 10% 1,430 moderate not evaluable TRAE (any grade)detailed results CheckMate 9LA, 2021 1.55 [0.94; 2.55]
MYSTIC (DT ; all population), 2020 0.31 [0.22; 0.44]
0.69 [0.14 ; 3.33 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 96% 1,430 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.44 [1.06; 1.94]
MYSTIC (DT ; all population), 2020 0.55 [0.39; 0.77]
0.89 [0.35 ; 2.28 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 94% 1,430 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 9LA, 2021 1.14 [0.38; 3.43]
MYSTIC (DT ; all population), 2020 1.91 [0.47; 7.71]
1.39 [0.59 ; 3.30 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 9LA, 2021 3.18 [1.94; 5.19]
MYSTIC (DT ; all population), 2020 1.47 [0.92; 2.35]
2.15 [1.01 ; 4.58 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 80% 1,430 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 9LA, 2021 3.48 [2.00; 6.05]
MYSTIC (DT ; all population), 2020 2.95 [1.51; 5.78]
3.26 [2.13 ; 4.99 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.88 [0.41; 149.53]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
6.74 [0.82 ; 55.04 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.37 [0.22; 0.63]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.09 [0.00 ; 2.47 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 82% 1,430 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.36 [0.09; 1.37]
MYSTIC (DT ; all population), 2020 0.06 [0.00; 1.01]
0.23 [0.05 ; 1.07 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 22% 1,430 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 9.87 [0.54; 181.39]
MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
11.58 [1.50 ; 89.46 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.97 [0.02; 49.27]
MYSTIC (DT ; all population), 2020 0.47 [0.02; 14.16]
0.65 [0.05 ; 8.42 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.97 [0.24; 3.93]
MYSTIC (DT ; all population), 2020 0.95 [0.24; 3.82]
0.96 [0.36 ; 2.58 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.06 [1.59; 31.30]
MYSTIC (DT ; all population), 2020 4.35 [0.93; 20.28]
5.59 [1.92 ; 16.29 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 3.97 [0.84; 18.81]
MYSTIC (DT ; all population), 2020 1.09 [0.39; 3.03]
1.81 [0.52 ; 6.25 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 46% 1,430 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.38 [0.60; 3.15]
1.38 [0.60 ; 3.15 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 13.52 [0.76; 239.13]
13.52 [0.76 ; 239.13 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.06; 56.82]
1.90 [0.06 ; 56.82 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.95 [0.07; 58.39]
MYSTIC (DT ; all population), 2020 5.73 [0.29; 114.82]
3.58 [0.38 ; 33.87 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 2.46 [0.47; 12.75]
2.46 [0.47 ; 12.75 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 7.55 [2.24; 25.47]
7.55 [2.24 ; 25.47 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 4.93 [0.57; 42.41]
4.93 [0.57 ; 42.41 ] CheckMate 9LA, 2021 1 0% 707 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.63 [0.39; 6.89]
MYSTIC (DT ; all population), 2020 0.16 [0.02; 1.30]
0.58 [0.06 ; 5.69 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 69% 1,430 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 0.71 [0.41; 1.24]
MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.20]
0.12 [0.00 ; 6.19 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 87% 1,430 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 7.74 [0.96; 62.17]
7.74 [0.96 ; 62.17 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 5.89 [0.29; 118.02]
MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
3.00 [0.28 ; 32.52 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 0% 1,430 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 11.88 [0.66; 213.53]
MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
3.25 [0.27 ; 38.64 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 35% 1,430 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.09 [0.44; 2.70]
MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.21 [0.01 ; 8.21 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 84% 1,430 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 9LA, 2021 1.17 [0.35; 3.88]
MYSTIC (DT ; all population), 2020 0.07 [0.00; 1.18]
0.38 [0.02 ; 5.93 ] CheckMate 9LA, 2021, MYSTIC (DT ; all population), 2020 2 69% 1,430 moderate not evaluable Alopecia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Anaemia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.12 [0.05; 0.28]
0.12 [0.05 ; 0.28 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Asthenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.86 [0.36; 2.05]
0.86 [0.36 ; 2.05 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Back pain AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.63 [0.10; 3.80]
0.63 [0.10 ; 3.80 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Constipation AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.90 [0.17; 21.07]
1.90 [0.17 ; 21.07 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Cough AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Decreased appetite AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.43 [0.40; 5.11]
1.43 [0.40 ; 5.11 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Diarrhoea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.12 [0.73; 6.17]
2.12 [0.73 ; 6.17 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Dyspnoea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.11 [0.37; 3.33]
1.11 [0.37 ; 3.33 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Fatigue AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 1.31 [0.52; 3.31]
1.31 [0.52 ; 3.31 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Nausea AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.63 [0.18; 2.25]
0.63 [0.18 ; 2.25 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Neutropenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.01 [0.00; 0.19]
0.01 [0.00 ; 0.19 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pruritus AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Pyrexia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.02; 47.95]
0.95 [0.02 ; 47.95 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Rash AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.95 [0.06; 15.23]
0.95 [0.06 ; 15.23 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.03 [0.00; 0.42]
0.03 [0.00 ; 0.42 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Vomiting AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 0.13 [0.02; 1.09]
0.13 [0.02 ; 1.09 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable Weight decreased AE (grade 3-4)detailed results MYSTIC (DT ; all population), 2020 2.86 [0.30; 27.64]
2.86 [0.30 ; 27.64 ] MYSTIC (DT ; all population), 2020 1 0% 723 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 19:11 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 36
- treatments: 856,634,861,416,864,769,980